Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Lovable Raises $330 Million at a $6.6 Billion Valuation as Alphabet’s CapitalG and Nvidia’s NVentures Double Down on “Vibe Coding”

Lovable Raises $330 Million at a $6.6 Billion Valuation as Alphabet’s CapitalG and Nvidia’s NVentures Double Down on “Vibe Coding”

On December 18, 2025, Stockholm-based AI software builder Lovable confirmed a blockbuster $330 million Series B that values the company at $6.6 billion—one of the biggest recent bets on the idea that building software can be as simple as describing it in plain English. The round was led by CapitalG (Alphabet’s growth fund) and Menlo Ventures’ Anthology fund, with an unusually deep roster of strategic backers joining in. Reuters+2Lovable+2 The size of the raise—and the speed of Lovable’s valuation jump—captures the current moment in AI-driven software development: investors and corporate tech giants are racing to back “agentic” tools that can
18 December 2025
···
Hudson Pacific Properties (HPP) Stock Update: Riot Games Deal, Debt Paydown, Reverse Split, and What Analysts Forecast on Dec. 18, 2025

Hudson Pacific Properties (HPP) Stock Update: Riot Games Deal, Debt Paydown, Reverse Split, and What Analysts Forecast on Dec. 18, 2025

LOS ANGELES — Hudson Pacific Properties, Inc. (NYSE: HPP) stock was sharply lower in Thursday trading, with shares recently around $10.31 after a steep one-day drop. The pullback lands as investors keep digesting a dense run of company headlines: a major West Los Angeles asset sale tied to Riot Games, a meaningful chunk of mortgage debt repaid, an updated fourth-quarter 2025 funds-from-operations (FFO) outlook, and a 1-for-7 reverse stock split that has made “before vs. after” comparisons unusually confusing across quotes and forecasts. Los Angeles Times+2Business Wire+2 What follows is a plain-English breakdown of the latest Hudson Pacific Properties news,
18 December 2025
·····
Cinemark Holdings, Inc. Stock (CNK) Slides After Morgan Stanley Downgrade: What Today’s News and 2026 Forecasts Mean

Cinemark Holdings, Inc. Stock (CNK) Slides After Morgan Stanley Downgrade: What Today’s News and 2026 Forecasts Mean

December 18, 2025 — Shares of Cinemark Holdings, Inc. (NYSE: CNK) fell sharply in Thursday trading as Wall Street digested a fresh analyst downgrade tied to a softer box office outlook. By mid‑afternoon, the stock was trading around $22 per share, down roughly 6% on the day. MarketBeat+1 The move puts Cinemark back in the spotlight at a time when the “theaters vs. streaming” debate has re-heated—and when investors are trying to decide whether 2025’s uneven box office was a temporary pothole or a warning sign for the business model. Below is what’s driving CNK stock on 12/18/2025, what analysts
18 December 2025
·····
Fermi Inc (FRMI) Stock on Dec. 18, 2025: Amazon-Tenant Claims Clash With Company Denial as Analysts Recut Targets After Project Matador Setback

Fermi Inc (FRMI) Stock on Dec. 18, 2025: Amazon-Tenant Claims Clash With Company Denial as Analysts Recut Targets After Project Matador Setback

Fermi Inc (NASDAQ & LSE: FRMI) is having the kind of week that turns a normal stock chart into modern art: sharp gaps, headline-driven swings, and investors trying to separate what’s confirmed from what’s merely energetic speculation. On December 18, 2025, FRMI closed at $8.34, down 7.98% on the day, after opening near $9.31 and trading as high as $9.33 and as low as $8.27—with roughly 7.52 million shares changing hands. Investing.com That move sits on top of an even bigger story: Fermi’s “first tenant” financing arrangement for its flagship Project Matador in Texas was terminated last week, triggering a
18 December 2025
······
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday trading, WVE stock fell roughly mid-single digits, hovering in the mid-$15 range after closing around $16.34 the prior session, according to market data and widely circulated market recaps. StockAnalysis+1 That pullback matters because it comes right after a dramatic early-December surge tied to Wave’s obesity program—and immediately following a large equity financing that materially changes the company’s cash position and
18 December 2025
····
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stock slid sharply on Thursday, December 18, 2025, after a regulatory filing revealed a leadership transition involving the company’s Chief Medical and Development Officer. In trading, CRNX fell roughly 8% to around the mid‑$40s, with the day’s range stretching from the low‑$40s to the high‑$40s as investors digested the update. Investing.com For a biotech stock—especially one in the middle of a major product launch and multiple late‑stage trials—management continuity matters. But so do fundamentals: Crinetics is no longer “just” a clinical-stage story. It recently reached a pivotal milestone with its first FDA-approved product, and its
18 December 2025
·····
Birkenstock (BIRK) Stock Slides on FY2026 Outlook as Tariffs and FX Bite, Despite a FY2025 Beat

Birkenstock (BIRK) Stock Slides on FY2026 Outlook as Tariffs and FX Bite, Despite a FY2025 Beat

Dec. 18, 2025 — Birkenstock Holding plc (NYSE: BIRK) delivered a classic “beat-and-drop” session: strong fiscal 2025 results and record revenue were overshadowed by a more cautious fiscal 2026 outlook that bakes in tariff and currency pressure. SEC+1 As of the latest available trade on Dec. 18, Birkenstock shares were at $42.58, down about 8% on the day, after swinging between $39.73 and $46.75 in heavy volume. The market’s message was blunt: investors liked what Birkenstock just did, but they’re repricing what it may earn next—especially if tariffs and foreign-exchange (FX) headwinds prove sticky. What’s happening with Birkenstock stock today
18 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because the Edgewise story is still mostly about future clinical readouts and regulatory path clarity, not current product revenue. The company is advancing late-stage work in muscular dystrophies (with its lead program, sevasemten) and also developing cardiac sarcomere modulators for conditions
18 December 2025
·····
ABM Industries (NYSE:ABM) Stock Slides on Dec. 18 After Q4 Earnings: WGNSTAR Deal, 2026 Outlook, Dividend Hike and Analyst Calls

ABM Industries (NYSE:ABM) Stock Slides on Dec. 18 After Q4 Earnings: WGNSTAR Deal, 2026 Outlook, Dividend Hike and Analyst Calls

ABM Industries Incorporated (NYSE: ABM) stock was sharply lower in Thursday trading (December 18, 2025), with shares recently changing hands near $43.13, down about 10.6% from the prior close after a volatile session that saw the stock trade between $43.02 and $47.63. The move follows a dense burst of company updates released on December 17: ABM’s fiscal fourth-quarter and full-year 2025 results, a fiscal 2026 outlook, a dividend increase, and a major acquisition announcement—plus fresh analyst commentary today that put margins and leverage back at the center of the debate. GlobeNewswire+2ABM+2 Why ABM stock is moving today The immediate catalyst
18 December 2025
·····
Inspire Medical Systems (INSP) Stock Plunges on Medicare Coding Reversal: Latest News, Analyst Forecasts, and What Investors Are Watching

Inspire Medical Systems (INSP) Stock Plunges on Medicare Coding Reversal: Latest News, Analyst Forecasts, and What Investors Are Watching

Inspire Medical Systems, Inc. (NYSE: INSP) stock tumbled sharply on Thursday, December 18, 2025, after a key Medicare coding tailwind that had fueled recent optimism suddenly looked far less certain. By early afternoon in the U.S. session, INSP was down in the mid-to-high teens, reflecting investor anxiety that a reimbursement “upgrade” tied to a specific billing code may not stick—at least not in the clean, nationwide way many had modeled. MarketBeat What happened to INSP stock on 18.12.2025? The immediate catalyst: two Medicare Administrative Contractors (MACs)—CGS and Noridian—reportedly pulled CPT code 64568 for hypoglossal nerve stimulation (HGNS) and redirected billing
18 December 2025
····
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC+1 Insmed stock was trading around $166.75 in the afternoon snapshot available from market data, down about 16% on the day, after touching an intraday low of $158.06 and high of $173.99. What happened to INSM stock on December 18, 2025 The selloff traces back to Insmed’s disclosure that its Phase
18 December 2025
·····
Upstart Stock News Today: UPST Jumps on Tech CU Partnership as Wall Street Weighs 2026 Outlook (Dec. 18, 2025)

Upstart Stock News Today: UPST Jumps on Tech CU Partnership as Wall Street Weighs 2026 Outlook (Dec. 18, 2025)

Upstart Holdings, Inc. (NASDAQ: UPST) is back in the spotlight on December 18, 2025 (18.12.2025), with the AI-lending stock pushing higher as traders react to fresh partner momentum in credit unions—and try to square that optimism with a still-volatile macro and a sharply divided analyst community. Shares were trading around the high-$40s on Thursday, up roughly 8% on the session at the time of this writing. Investing.com That move follows a choppy stretch for UPST, where single-day swings have become a feature, not a bug. Today’s catalyst is fairly clear: a new credit union partnership that reinforces Upstart’s strategy of
18 December 2025
·····
1 … 616 617 618 619 620 … 885

Stock Market Today

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

7 February 2026
LONDON, February 7, 2026, 08:48 GMT — Market closed Lloyds Banking Group shares finished Friday higher after the lender flagged another round of share buybacks, helping to steady the stock at the end of a volatile two-day swing driven by shifting expectations for UK interest rates. With London markets closed for the weekend, the focus moves to Monday’s open and whether rate-cut pricing keeps easing pressure on bank earnings. Lloyds is a UK-focused lender, and investors tend to treat it as a clean play on domestic growth, mortgages and the direction of Bank Rate. That makes the stock quick to
Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
Go toTop